1. Home
  2. KRMD vs CNTB Comparison

KRMD vs CNTB Comparison

Compare KRMD & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

N/A

Current Price

$3.43

Market Cap

146.4M

Sector

Health Care

ML Signal

N/A

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

N/A

Current Price

$0.62

Market Cap

140.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRMD
CNTB
Founded
1980
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.4M
140.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRMD
CNTB
Price
$3.43
$0.62
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
★ $6.13
$5.71
AVG Volume (30 Days)
173.2K
★ 599.6K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
N/A
EPS
★ N/A
N/A
Revenue
★ $41,127,366.00
$64,000.00
Revenue This Year
$17.24
$7,473.67
Revenue Next Year
$16.13
$240.46
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 22.23
N/A
52 Week Low
$2.86
$0.55
52 Week High
$6.61
$3.82

Technical Indicators

Market Signals
Indicator
KRMD
CNTB
Relative Strength Index (RSI) 51.35 36.76
Support Level $3.00 N/A
Resistance Level $3.41 $2.62
Average True Range (ATR) 0.26 0.07
MACD 0.02 0.01
Stochastic Oscillator 37.83 33.75

Price Performance

Historical Comparison
KRMD
CNTB

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Share on Social Networks: